Accendra Health
Provides home medical equipment and supplies through Apria and Byram.
Something off on this page? Send us feedback.
Profile
Provides home-based care products, technology, and services through Apria and Byram, connecting patients, providers, and insurers beyond the hospital. Continuing operations are a single reporting segment shaped by diabetes, sleep therapy, respiratory therapy, ostomy, wound care, and urology categories.
Runs a home-based care platform built around Apria and Byram Healthcare. Apria focuses on durable medical equipment supplies and in-home clinical support for sleep apnea, respiratory care, and negative pressure wound therapy. Byram adds DME supplies and education for diabetes, urology, ostomy, wound care, incontinence, and breast pumps.
Connects patients, providers, and insurers with products, technology, and services that support health beyond the hospital. The business is run from Virginia and reflects the former Patient Direct platform after the hospital products and distribution business was sold.
Operates as one continuing reporting segment, with commercial payors, Medicare, and Medicaid shaping reimbursement. The mix depends on chronic-care categories and on payor contracts, including large commercial relationships.
Company facts
Categories
Key statistics
Year to date −47.4% · Average volume (30d) 1.6M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | UBS | Reiterate | Neutral | $4.50 | $1.50 | |
| Aug 11, 2026 | Robert W. Baird | Target | $6 | $1.50 | ||
| Aug 11, 2026 | Citigroup | Downgrade | Buy | Neutral | ||
| Aug 10, 2026 | UBS | Upgrade | Neutral | Buy | ||
| Aug 10, 2026 | Jefferies | Downgrade | Underperform |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026Q2 FY26 | −$0.08 | −$0.19 | −126.6% | $628.7M | $613.2M | −2.5% | −50.00% |
| May 11, 2026Q1 FY26 | −$0.06 | −$0.04 | +33.3% | $644.2M | $627.8M | −2.5% | −17.74% |
| Feb 19, 2026Q4 FY25 | $0.22 | $0.21 | −4.5% | $713.4M | $709.0M | −0.6% | +5.24% |
| Oct 30, 2025Q3 FY25 | $0.23 | $0.25 | +8.7% | $714.8M | $697.3M | −2.5% | −19.96% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $2.63B | $681.9M | $697.3M | $709.0M | $627.8M | $613.2M | |
| Gross profit | $526.0M | $324.6M | $322.2M | $323.3M | $278.0M | $263.4M | |
| Operating income | $124.0K | $56.7M | $56.4M | $51.8M | $22.8M | −$35.2M | |
| Net income | −$25.0M | −$869.1M | −$150.3M | −$56.3M | −$6.5M | −$89.1M | |
| Diluted EPS | −$0.32 | −$11.30 | −$1.94 | −$0.73 | −$0.08 | −$1.16 | |
| Gross margin | 20.0% | 47.6% | 46.2% | 45.6% | 44.3% | 43.0% | |
| Operating margin | 0.0% | 8.3% | 8.1% | 7.3% | 3.6% | -5.7% |
Fiscal years (4-quarter sums)FY21 $9.79B · FY22 $9.96B · FY23 $10.33B · FY24 $6.66B · FY25 $4.72B
Revenue by product · Q2 FY26
Revenue by geography · FY24
Balance sheet, Jun 30, 2026Cash & short-term investments $7.7M · Total debt $1.78B · Total assets $2.11B · Shareholders' equity −$550.9M
Dividends
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Dec 14, 2021 | Dec 15 | Dec 31 | $0.002 | |
| Sep 14, 2021 | Sep 15 | Sep 30 | $0.002 |
Ownership
Shares outstanding 76.58M · Float 56.19M · 73.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Coliseum Capital Management, LLC | 13.10M | 16.90% | 13D | Nov 14, 2025 |
| BlackRock, Inc. | 5.45M | 7.10% | 13G | Oct 2, 2025 |
| Kevin M. Webb | 4.29M | 5.61% | 13G | Mar 30, 2026 |
| Edward A. Pesicka · director, officer: President & CEO | 1.07M | 1.40% | Form 4 | May 19, 2026 |
| Perry A. Bernocchi · officer: EVP, Chief Operating Officer | 313.9K | 0.41% | Form 4 | May 19, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- AdaptHealth
Broad HME rival across sleep, respiratory, diabetes, and home supplies
- Cardinal Health
At-home supply channel for diabetes, ostomy, urology, and wound care
- Linde
Public parent of Lincare, a large respiratory homecare provider
- Viemed Healthcare
Home respiratory and sleep-care peer with clinical support model
- Inogen
Respiratory device rival in oxygen therapy and homecare products
- CVS Health
PBM, retail-pharmacy, and home-care channel pressure
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Accendra Health | $1.20 | −1.54% | $92.7M | — | — | 0.0 | −10.1% |
| AdaptHealth | $5.77 | −0.52% | $787.8M | — | — | 0.3 | −7.5% |
| Cardinal Health | $232.64 | −0.84% | $54.93B | 32.4 | 18.7 | 0.2 | +5.8% |
| Linde | $489.36 | −0.03% | $226.45B | 31.6 | 26.2 | 6.4 | +9.4% |
| Viemed Healthcare | $9.00 | +1.93% | $335.9M | 24.2 | 17.9 | 1.1 | +23.9% |
| Inogen | $5.50 | −0.09% | $148.9M | — | — | 0.4 | +3.0% |
| CVS Health | $93.07 | +0.02% | $118.74B | 24.6 | 11.5 | 0.3 | +7.3% |
| Median | 28.1 | 18.3 | 0.4 | +6.6% |